CBD Life Sciences Inc. (CBDL)

CBD Life Sciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	0.1	0.1	0.17	0.16	0.08
Revenue Growth (YoY)	1.05%	-41.79%	4.31%	92.17%	-63.09%
Cost of Revenue	0.06	-0.06	0.09	0.07	0.06
Gross Profit	0.04	0.15	0.08	0.09	0.03
Selling, General & Admin	0.14	0.8	0.1	0.89	6.15
Other Operating Expenses	-	-	0	0	0.02
Operating Expenses	0.14	0.8	0.16	0.95	6.17
Operating Income	-0.1	-0.65	-0.08	-0.86	-6.14
Other Non Operating Income (Expenses)	0.05	-0.11	-	-	-
EBT Excluding Unusual Items	-0.05	-0.76	-0.08	-0.86	-6.14
Pretax Income	-0.05	-0.76	-0.08	-0.86	-6.14
Net Income	-0.05	-0.76	-0.08	-0.86	-6.14
Net Income to Common	-0.05	-0.76	-0.08	-0.86	-6.14
Shares Outstanding (Basic)	4,110	642	136	136	78
Shares Outstanding (Diluted)	4,110	642	136	136	78
Shares Change (YoY)	540.48%	372.93%	-	73.92%	2403.73%
EPS (Basic)	-0.00	-0.00	-0.00	-0.01	-0.08
EPS (Diluted)	-0.00	-0.00	-0.00	-0.01	-0.08
Free Cash Flow	-0.14	0.02	-0.02	-0.87	-6.44
Free Cash Flow Per Share	-	-	-	-0.01	-0.08
Gross Margin	42.20%	157.79%	47.70%	53.48%	32.90%
Operating Margin	-103.44%	-667.33%	-47.01%	-536.57%	-7364.79%
Profit Margin	-49.77%	-778.18%	-47.01%	-536.57%	-7364.79%
Free Cash Flow Margin	-141.52%	15.43%	-9.96%	-544.92%	-7728.80%
EBITDA	-	-0.59	-0.02	-0.81	-
EBITDA Margin	-	-	-13.77%	-	-
D&A For EBITDA	-	0.06	0.06	0.05	-
EBIT	-0.1	-0.65	-0.08	-0.86	-6.14
EBIT Margin	-103.44%	-	-47.01%	-	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 5, 2026

Data Sources Report a data error